Literature DB >> 12160089

Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.

Sandra Z Haslam1, Janet R Osuch, A M Raafat, L J Hofseth.   

Abstract

Endogenous estrogen exposure has long been implicated in the causation of breast cancer through a mechanism of epithelial cell proliferation. Whether estrogen, progesterone, or both exhibit mitogenic activity and promote carcinogenesis in the human breast has been the subject of considerable debate. The purpose of this review article is to examine the evidence for the effects of hormone replacement therapy in its various forms on the biology of the postmenopausal breast both in humans and in an animal model, and to identify the gaps in knowledge that research will need to address to further understand this complex issue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160089     DOI: 10.1023/a:1015726608146

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  68 in total

1.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacob; M J Thun
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Mammographic breast density during hormone replacement therapy: differences according to treatment.

Authors:  E Lundström; B Wilczek; Z von Palffy; G Söderqvist; B von Schoultz
Journal:  Am J Obstet Gynecol       Date:  1999-08       Impact factor: 8.661

3.  Combined oestrogen-progestogen replacement and breast cancer risk.

Authors:  I Persson; J Yuen; L Bergkvist; H O Adami; R Hoover; C Schairer
Journal:  Lancet       Date:  1992-10-24       Impact factor: 79.321

4.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

Authors:  K K Steinberg; S B Thacker; S J Smith; D F Stroup; M M Zack; W D Flanders; R L Berkelman
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

5.  Mammographic changes in women on hormonal replacement therapy.

Authors:  C T Erel; H Seyisoğlu; M L Sentürk; C Akman; G Ersavaşti; A Benian; C Uras; A Altuğ; E Ertüngealp
Journal:  Maturitas       Date:  1996-08       Impact factor: 4.342

6.  Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors.

Authors:  H Olsson; H Jernström; P Alm; H Kreipe; C Ingvar; P E Jönsson; S Rydén
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Mammographic parenchymal patterns and breast cancer risk.

Authors:  A F Saftlas; M Szklo
Journal:  Epidemiol Rev       Date:  1987       Impact factor: 6.222

8.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.

Authors:  I Persson; H O Adami; L Bergkvist; A Lindgren; B Pettersson; R Hoover; C Schairer
Journal:  BMJ       Date:  1989-01-21

Review 9.  Role of hormones in mammary cancer initiation and progression.

Authors:  I H Russo; J Russo
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

10.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

View more
  13 in total

Review 1.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

Review 2.  Challenges to defining a role for progesterone in breast cancer.

Authors:  Carol A Lange
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

Review 3.  Progesterone and breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Womens Health (Lond)       Date:  2008-03

4.  Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats.

Authors:  Ayelen L Gomez; Melisa B Delconte; Gabriela A Altamirano; Lucia Vigezzi; Veronica L Bosquiazzo; Luís F Barbisan; Jorge G Ramos; Enrique H Luque; Mónica Muñoz-de-Toro; Laura Kass
Journal:  Horm Cancer       Date:  2017-01-11       Impact factor: 3.869

Review 5.  Optimizing mouse models for precision cancer prevention.

Authors:  Clémentine Le Magnen; Aditya Dutta; Cory Abate-Shen
Journal:  Nat Rev Cancer       Date:  2016-02-19       Impact factor: 60.716

6.  Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.

Authors:  Millie A Behera; Qunsheng Dai; Rachana Garde; Carrie Saner; Emily Jungheim; Thomas M Price
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-08-18       Impact factor: 4.310

7.  Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.

Authors:  Rebecca E De Angel; Jorge M Blando; Matthew G Hogan; Michael A Sandoval; Dharmika S P Lansakara-P; Sarah M Dunlap; Stephen D Hursting; Zhengrong Cui
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

8.  Estrogen plus progestin and risk of benign proliferative breast disease.

Authors:  Thomas E Rohan; Abdissa Negassa; Rowan T Chlebowski; Norman L Lasser; Anne McTiernan; Robert S Schenken; Mindy Ginsberg; Sylvia Wassertheil-Smoller; David L Page
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08-25       Impact factor: 4.254

9.  Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Authors:  Martin A Rivas; Leandro Venturutti; Yi-Wen Huang; Roxana Schillaci; Tim Hui-Ming Huang; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2012-05-14       Impact factor: 6.466

10.  A 5' distal palindrome within the mouse mammary tumor virus-long terminal repeat recruits a mammary gland-specific complex and is required for a synergistic response to progesterone plus prolactin.

Authors:  Joseph E Morabito; Josephine F Trott; Dorian M Korz; Heather E Fairfield; Sarah H Buck; Russell C Hovey
Journal:  J Mol Endocrinol       Date:  2008-06-04       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.